Immunomodulatory Effects of Combination Therapy with Bushen Formula plus Entecavir for Chronic Hepatitis B Patients

Table 1

Baseline characteristics of 220 CHB patients .

Group ()	Sex (M/F)	Age (years)	ALT (U/l)	AST (U/l)	HBV DNA (lgIU/ml)	HBsAg (lgIU/ml)	HBeAg(+) ()
T1 (59)	38/21	37.0 (32.0–42.0)	40.0 (26.0–73.0)	33.0 (26.0–60.0)	5.48 (4.31–7.05)	3.64 (3.22–4.12)	38
T2 (42)	26/16	41.5^a (37.3–46.8)	22.0^b (14.5–28.2)	24.0^e (19.0–30.5)	N.A.	3.37 (2.92–4.00)	18
C1 (78)	59/19	34.0 (29.0–41.0)	53.0^c (34.0.0–93.0)	42.0^f (29.0–65.0)	7.11 (5.17–7.95)	3.99 (3.34–4.16)	54
C2 (41)	36/5	39.0 (33.0–52.5)	25.0^d (22.0–28.8)	25.0^g (22.0–28.8)	N.A.	3.56 (3.10–3.80)	19

Notes: M: male; F: female; ALT: alanine aminotransferase; AST: aspartate transaminase; HBV: hepatitis B virus; HBsAg: hepatitis B surface antigen; HBeAg: hepatitis B e antigen. ^a, compared with C1; ^b, compared with T1; ^c, compared with T1; ^d, compared with C1; ^e, compared with T1; ^f, compared with T1; ^g, compared with C1.